1 / 45

SPECIFIC QUALITY PROBLEMS WITH ANTIBIOTICS AND ANTITUBERCULOTICS

1-3. SPECIFIC QUALITY PROBLEMS WITH ANTIBIOTICS AND ANTITUBERCULOTICS. Pr A. NICOLAS, PhD Head of the French Laboratories and Controls Directorate AFSSAPS.

paul2
Download Presentation

SPECIFIC QUALITY PROBLEMS WITH ANTIBIOTICS AND ANTITUBERCULOTICS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 1-3 SPECIFIC QUALITY PROBLEMS WITH ANTIBIOTICS AND ANTITUBERCULOTICS Pr A. NICOLAS, PhD Head of the French Laboratories and Controls Directorate AFSSAPS Interregional Seminar for Quality Control Laboratories involved in WHO Prequalification Programme and/or participating in respective sampling and testing projects, Nairobi, Kenya, 23-25 September 2009

  2. ANTIBIOTICS AND ANTITUBERCULOTICS • Classification • Origin • Drug quality reports • Fermentation products • Impact on the composition of a monograph • Antituberculosis dosage forms • Conclusion

  3. ANTIBIOTICS - CLASSIFICATION • Very diverse class of compounds • Generally grouped according chemical structures • Aminoglysides • Cephalosporins and related beta lactams • Glycopeptides • Macrolides • Penicillins • Quinolones • Sulphonamides and diaminopyrimidines • Tetracyclines

  4. ANTITUBERCULOSIS - CLASSIFICATION • Miscellaneous group of antibacterials • Include • Cycloserine • Ethambutol • Isoniazid • Pyrazinamide • Rifampicin

  5. WHO List of Prequalified Medicinal Products • Prequalified antituberculosis products (june 2009) • Cycloserine • Ethambutol • Isoniazid • Ethionamide • Pyrazinamide • Ethambutol + Isoniazid • Ethambutol + Isoniazid + Rifampicin • Ethambutol + Isoniazid + Pyrazinamide + Rifampicin • Isoniazid + Rifampicin • Isoniazid + Pyrazinamide + Rifampicin

  6. Drug Quality Reports Affecting USAID-assisted Countries (1) • USP Drug Quality and Information Program • Updated june 2009 • Repository of publicly-available information to raise awereness of the problem of counterfeit and substandard medicines • More often cited drugs : antimalarials, antiretrovirals • But also : antibiotics, antituberculosis products

  7. Drug Quality Reports Affecting USAID-assisted Countries (2) • Ghana • 13/08/2004 Counterfaiting of Ampicillin (root crop cassava) • Nigeria • 29/05/2008 • Augmentin (amoxicillin/clavulanic acid) • Ampicillin • 15/05/2009 • Amoxicillin, ciprofloxacin, ampicillin, cloxacillin, erythromycin

  8. Drug Quality Reports Affecting USAID-assisted Countries (3) • Sierra Leone • 17/06 2008 : chloraphecol, tetracycline • 9/06/2008 : amoxicillin, ampicillin • South Africa • 27/05/2009 • Antib-4 (pyrazinamide, ethambutol, isoniazid, rifampicin) • Ebsar (isoniazid + rifampicin) • Tanzania • 5/10/2008 : antibiotics • Uganda • 1/10/2005 : cloxacillin

  9. ORIGIN • These active substances could be obtained by : • synthetic route • semi-synthetic route derived from fermentation product by process involving at least cleavage and/or formation of covalent bonds followed by extraction/purification steps • fermentation • The origin impacts the purity profile, choice of the analytical methods and their performance

  10. REFERENCES : ICH and Ph. Eur. • Guideline ICH Q3A(R2) « Impurity in New Drug Substances » • Ph. Eur. Chapter 5.10 «Control of Impurities in substances for pharmaceutical use» • Ph. Eur. General monograph (2034) «Substances for pharmaceutical use» do not cover « fermentation products and semi-synthetic products derived therefrom » for application of reporting, identification and qualification thresholds

  11. THRESHOLDS FOR ORGANIC IMPURITIES IN ACTIVE SUBSTANCES (General case)

  12. PRODUCTS OF FERMENTATION (1) • Relevant monograph from Ph. Eur. « Products of fermentation (1468) » This monograph applies to : • products obtained by semi-synthesis from a product of fermentation and those obtained by biocatalytic transformation • whole broth concentrates or raw fermentation products A complex class of compounds with many analytical challenges

  13. PRODUCTS OF FERMENTATION (2) • Fermentation processes are biosynthetic pathways consisting of parallel reactions • Some antibiotics are mixtures of structurally related substances • Not always clear which of these substances contribute to activity (active or impurity ?) • Separationnot always achievable

  14. PRODUCTS OF FERMENTATION (3) • Biosynthetic pathways difficult to control (variation from batch to batch) • Different strains of same species may lead to different impurity profiles • Large differences in media components in fermentation may lead to different impurity profiles

  15. MONOGRAPH – DEFINITION (1) • Substances obtained by synthetic or semi-synthetic route correspond to a major known compound • Substances obtained by fermentation are often but not always defined as mixtures • The name of the strain is indicated

  16. MONOGRAPH – DEFINITION (2) • Synthetic : ciprofloxacin 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid. • Semisynthetic : rifampicin 2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-Pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[[(4-methylpiperazin-1-yl)imino]methyl]-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienimino)naphto[2,1-b]furan-21-yl acetate Semisynthetic antibiotic obtained from rifamycin SV.

  17. MONOGRAPH – DEFINITION (3) • Fermentation leading to a known major compound : josamycin Josamycin is a macrolide antibiotic produced by certain strains of Streptomyces narbonensis var. josamyceticus var. nova, or obtained by any other means. The main component is…… • Fermentation leading to a mixture : gentamicin Mixture of the sulphates of antimicrobial substances produced by Micromonospora purpurea, the main components being gentamicins C1, C1a, C2, C2a and C2b.

  18. MONOGRAPH - IDENTIFICATION • Synthetic and semisynthetic • Identification by IR spectroscopy (2.2.24) • Mixtures obtained by fermentation • IR if structures of the individual compounds are very similar : erythromycin • Identification by  examination of the chromatograms obtained in the test for composition • Gentamicin : the chromatogram obtained with the test solution shows 5 principal peaks having the same retention times as the 5 principal peaks in the chromatogram obtained with reference solution (gentamicin sulphate CRS).

  19. MONOGRAPH - TESTS • Composition • Used to specify complex mixture such as some fermented polypeptides (tyrothricin) or aminoglycosides(gentamicin) • Related substances • ICH impurity limits/thresholds cannot be applied because of wide variety in purity and complexity • Not possible to establish one fixed set of thresholds for identification and qualification • Specifications should be derived on a case by case basis considering batch results of various suppliers

  20. MONOGRAPH - TESTS COMPOSITION In the case of mixture a « composition test » is described • Composition. Liquid chromatography (2.2.29): use the normalisation procedure taking into account only the peaks due to gentamicins C1, C1a, C2, C2a and C2b; use the chromatogram supplied with gentamicin sulphate CRS to identify the corresponding peaks. • Limits • gentamicin C1: 20.0 per cent to 40.0 per cent, • gentamicin C1a: 10.0 per cent to 30.0 per cent, • sum of gentamicins C2, C2a, and C2b: 40.0 per cent to 60.0 per cent

  21. COMPOSITION – GENTAMICIN (1) • Known structures of 5 components

  22. COMPOSITION – GENTAMICIN (2) J. Pharm. Biomed. Analysis, 2007, 45, 257-262

  23. MONOGRAPH - TESTS RELATED SUBSTANCES (1) • Same method as for composition but different specifications • Content in impurities can be very high and chemical structures are not always known • Gentamicin Limits (for related substances eluting before gentamicin C1a): • any impurity: maximum 3.0 per cent • total: maximum 10.0 per cent

  24. MONOGRAPH - TESTS RELATED SUBSTANCES (3) • Threshold for « any unspecified impurity » in current antibiotics monographs from Ph. Eur. • Ciprofloxacine : 0.1 % • Cefradine : 0.25 % • Amoxicillin trihydrate : 1 % • Gentamicin sulphate : 3.0 %

  25. MONOGRAPH ASSAY – MICROBIOLOGICAL TITRATION • Microbiological assay of antibiotics (2.7.2) • Two methods • A. Diffusion method (19 antibiotics) • B. Turbidimetric method (14 antibiotics) • Indication of the reagents, micro-organisms, pH, temperature • Chapter 5.3. Statistical analysis of results of biological assays and tests • Use of CombiStats www.edqm.eu

  26. MONOGRAPH - ASSAY HPLC (1) • ASSAY – HPLC (2.2.29) • For synthetic and semi-synthetic drugs • For mixtures obtained by fermentation if similar activity of the individual compounds • Possibilty of sums of active substances • HPLC/UV • For chromophoric compounds (general case) • Or after derivatization (amikacine)

  27. MONOGRAPH - ASSAY HPLC (2) • Erythromycin • Content: • sum of the contents of erythromycin A, erythromycin B and erythromycin C: 93.0 per cent to 102.0 per cent (anhydrous substance), • erythromycin B: maximum 5.0 per cent, • erythromycin C: maximum 5.0 per cent.

  28. MONOGRAPH - ASSAY HPLC (3) • Other detection modes(aminosides) • HPLC/PAD(pulsed amperometric detection), Ph. Eur and US, Ph. Int. • Difficult to handle, poor precision • Noisy, high disregard limit (1.0 % for framycetine and neomycine sulphate) • HPLC/ELSD • Gentamicin sulphate (Chinese Ph.) • Simultaneous determination of content in sulphates (in place of titration)

  29. MONOGRAPH - STORAGE • General conditions : in airtight container • Specific conditions • Protected from light: tiamuline • Multiple conditions • In an airtight container, at a temperature of 2 °C to 8 °C : potassium clavulanate • Under nitrogen in an airtight container, protected from light, at a temperature not exceeding 25 °C : rifampicin

  30. MONOGRAPH - TRANSPARENCY LIST (IMPURITIES) • List of specified and other detectable impurities (for definition see Ph. Eur. General monograph 2034) • All cases • Absence to a very long list • Nystatin, Josamycin, tyrothricin : no list • Tiamuline : 6 specified impurities, 12 other detectable impurities • GRAHEK R and ZUPANCIC-KRALJ J. Pharm. Biomed. Anal. XXX(2009)xxx in press Identification of gentamicin impurities by LC tandem mass spectrometry : 17 impurities

  31. ANTITUBERCULOSIS DOSAGE FORMS • Ph. Int., 1st Suppl : 6 new monographs including 2, 3 and 4 component fixed-dose preparations • Doxycycline capsules • Isoniazid and ethambutol hydrochloride tablets • Rifampicin capsules and tablets • Rifampicin and isoniazid tablets • Rifampicin, isoniazid and pyrizinamide tablets • Rifampicin, isoniazid, pyrizinamide and ethambutol hydrochloride tablets • Introduction of dissolution test in monographs for tablets and capsules : doxycycline, isoniazid

  32. 4 COMPONENTS ANTITUBERCULOSIS TABLETS • Rifampicin (150 mg), isoniazid (75 mg), pyrizinamide (400 mg) and ethambutol hydrochloride (275 mg) tablets • Rifampicin : semisynthetic antibiotic obtained from rifamycin SV. • Isoniazid, pyrizinamide and ethambutol hydrochloride : synthetic compounds • Monographs in Ph. Eur., USP, Ph. Int., Chinese

  33. ETHAMBUTOL, HCl

  34. ISONIAZID

  35. PYRAZINAMIDE

  36. RIFAMPICIN

  37. 4 COMPONENTS ANTITUBERCULOSIS TABLETS – Ph. Int. (1) • Rifampicin (150 mg), isoniazid (75 mg), pyrizinamide (400 mg) and ethambutol hydrochloride (275 mg) tablets • Ph. Int. (4th Edition, 1st supplement 2008) • Identification • Tests A and B (retention time/HPLC for assay) or • Test C : 2 TLC systems (different stationary phases)

  38. 4 COMPONENTS ANTITUBERCULOSIS TABLETS – Ph. Int. (2) • Impurities • Rifampicin-related substances (RP-HPLC-UV) • Addition product : 3-formylrifamycin SV (specified impurity of rifampicin limited to 0.5% in the API) and isoniazid : 5.0 % • Rifampicin quinone : 4.0 % • Any other impurity : 1.5 % • Total : 10.0 % • Disregard limit : 0.1 % • Impurities in API • 3-formylrifamycin SV : 0.5 % • Rifampicin quinone : 1.5 % • Any other impurity : 1.0 %

  39. 4 COMPONENTS ANTITUBERCULOSIS TABLETS - Ph. Int. (3) • No dissolution test • Assay • First RP-HPLC-UV system for isoniazid, pyrizinamide and ethambutol hydrochloride • Second RP-HPLC-UV system for rifampicin • Specifications : 90.0 to 110.0 % of the amounts stated on the label

  40. 4 COMPONENTS ANTITUBERCULOSIS TABLETS - USP • Identification By retention time (2 HPLC systems) • Dissolution Not less than 75 % of the labeled amounts of each active substance in 45 min • Impurities No test • Assay 2 HPLC systems : content 90.0 to 110.0 % in each component

  41. ANTIBIOTICS – COUNTERFAITING (1) • Screening of some of the most conterfeited antibiotics in a single chromatographic run Gaudiano M.C. et coll, J. Pharm. Biomed. Anal., 2008, 48, 303-309 RP-HPLC method, elution by gradient, detection 230 nm Ampicillin, amoxicillin + clavulanic acid, doxycycline, cloxacillin, chloramphenicol

  42. ANTIBIOTICS – COUNTERFAITING (2)

  43. MACROLIDES – COUNTERFAITING (1) • Fast chemical identification system for screening of counterfeit drugs of macrolide antibiotics CHANG-QIN HU et coll., J. Pharm. Biomed. Anal., 2006, 540, 68-74 • Two color reactions + 2 TLC • Sreening of 10 macrolides

  44. MACROLIDES – COUNTERFAITING (2)

  45. CONCLUSION • Products from fermentation (antibiotics/antituberculosis) are a challenge for analysts and for the authorities • Complex mixtures • All compounds not well known (impurity profile) • Specific analytical methods (HPLC/amperometry) • Content determined by activity assay • Products obtained by synthetic routes • Obey to ICHQ3A (R2) • Large place for classical HPLC methods coupled to UV detection • Impurity profile well known

More Related